Previous 10 | Next 10 |
CNX Midstream Partners LP (NYSE: CNXM ) -31% on dividend cut . More news on: CNX Midstream Partners LP, Verastem, Inc., Whiting Petroleum Corporation, Stocks on the move, , Read more ...
Gainers: Mesoblast (NASDAQ: MESO ) +116% . More news on: Mesoblast Limited, Medigus Ltd., Microbot Medical Inc., Stocks on the move, , Read more ...
Shares of Mesoblast (NASDAQ: MESO) rose as much as 218.9% after the company reported promising early-stage results from a small study in COVID-19 patients with acute respiratory distress syndrome (ARDS). The Australian stem cell company's product candidate, remestemcel-L, was administered to...
Mesoblast (NASDAQ: MESO ) +119% as cell therapy shows significant benefit in COVID-19 patients. More news on: Mesoblast Limited, Medigus Ltd., Pluristem Therapeutics Inc., Stocks on the move, , Read more ...
Thinly traded Mesoblast Limited (NASDAQ: MESO ) rockets 51% premarket on average volume in reaction to its announcement of an 83% (n=10/12) survival rate in ventilator-dependent COVID-19 patients who were treated with its allogeneic mesenchymal stem cell product candidate remes...
Key points: 83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory distress syndrome (ARDS) treated with two infusions of Mesoblast’s allogeneic cell therapy remestemcel-L within the first five days under emergency compassiona...
NEW YORK, April 17, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX:MSB) today announced that results using its allogeneic mesenchymal stem cell product candidate remestemcel-L in patients with inflammatory lung disease have been selected for oral presentation at the 2020 Inte...
Tiziana Life Sciences PLC (NASDAQ: TLSA ) +68% on inhalable treatment for COVID-19. More news on: Tiziana Life Sciences PLC, Nautilus, Inc., Exantas Capital Corp., Stocks on the move, , Read more ...
Mesoblast's (NASDAQ: MESO ) remestemcel-L will be evaluated in a placebo-controlled trial in 240 patients with acute respiratory distress syndrome (ARDS) caused by COVID-19. More news on: Mesoblast Limited, Healthcare stocks news, Read more ...
NEW YORK, April 08, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L will be formally evaluated in a randomized, placebo-controlled trial in 240 patients with acute respiratory...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 14:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for MESO on July 23, 2024 12:57PM ET. MESO was trading at $8.29 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 2 - H...
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...